Huons gets KFDA approval for combination drug
Published: 2012-02-02 06:56:00
Updated: 2012-02-02 06:56:00
Huons and CTC Bio said Tuesday that the Korea Food and Drug Administration has given the green light to Arigrel, which combines the two most commonly prescribed medicines, clopidogrel and aspirin, for the treatment of arteriosclerosis.
“Arigrel may ensure patient compliance as it can help redu...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
